Large-scale downstream processing of viral vectors and vaccines can face a range of obstacles different from those of many biotherapeutics. These challenges mostly arise from the size and complexity of the vector, which can affect product purity and recovery. Improvements of purification tools are necessary to overcome these challenges and must be engineered for easy scalability to meet manufacturing demands. The following case studies examine the benefits of innovative resins and purification strategies.
|